182 related articles for article (PubMed ID: 28544814)
21. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention.
Ramsay E; Alnajim J; Anantha M; Zastre J; Yan H; Webb M; Waterhouse D; Bally M
Eur J Pharm Biopharm; 2008 Mar; 68(3):607-17. PubMed ID: 17904831
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.
Rujkijyanont P; Photia A; Traivaree C; Monsereenusorn C; Anurathapan U; Seksarn P; Sosothikul D; Techavichit P; Sanpakit K; Phuakpet K; Wiangnon S; Chotsampancharoen T; Chainansamit SO; Kanjanapongkul S; Meekaewkunchorn A; Hongeng S
BMC Cancer; 2019 Oct; 19(1):961. PubMed ID: 31619207
[TBL] [Abstract][Full Text] [Related]
23. Formulation and characterization of liposomes containing drug absorption enhancers for optimized anti-HIV and antimalarial drug delivery.
Kheoane PS; Enslin GM; Tarirai C
Drug Deliv Transl Res; 2023 May; 13(5):1358-1371. PubMed ID: 36443635
[TBL] [Abstract][Full Text] [Related]
24. The role of pH and ring-opening hydrolysis kinetics on liposomal release of topotecan.
Fugit KD; Anderson BD
J Control Release; 2014 Jan; 174():88-97. PubMed ID: 24231406
[TBL] [Abstract][Full Text] [Related]
25. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
[TBL] [Abstract][Full Text] [Related]
26. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
[TBL] [Abstract][Full Text] [Related]
27. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation.
Liu JJ; Hong RL; Cheng WF; Hong K; Chang FH; Tseng YL
Anticancer Drugs; 2002 Aug; 13(7):709-17. PubMed ID: 12187327
[TBL] [Abstract][Full Text] [Related]
28. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.
Park JR; Scott JR; Stewart CF; London WB; Naranjo A; Santana VM; Shaw PJ; Cohn SL; Matthay KK
J Clin Oncol; 2011 Nov; 29(33):4351-7. PubMed ID: 22010014
[TBL] [Abstract][Full Text] [Related]
29. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
Zamboni WC; Stewart CF; Thompson J; Santana VM; Cheshire PJ; Richmond LB; Luo X; Poquette C; Houghton JA; Houghton PJ
J Natl Cancer Inst; 1998 Apr; 90(7):505-11. PubMed ID: 9539245
[TBL] [Abstract][Full Text] [Related]
30. Absolute bioavailability studies of a new oral topotecan formulation in Chinese patients using UHPLC-MS/MS.
Li N; Han X; Yang J; Gui L; Song Y; Du P; Shi Y
J Pharm Biomed Anal; 2013 Mar; 76():252-6. PubMed ID: 23354352
[TBL] [Abstract][Full Text] [Related]
31. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
[TBL] [Abstract][Full Text] [Related]
32. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models.
Webb MS; Harasym TO; Masin D; Bally MB; Mayer LD
Br J Cancer; 1995 Oct; 72(4):896-904. PubMed ID: 7547237
[TBL] [Abstract][Full Text] [Related]
33. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer.
Webb MS; Logan P; Kanter PM; St-Onge G; Gelmon K; Harasym T; Mayer LD; Bally MB
Cancer Chemother Pharmacol; 1998; 42(6):461-70. PubMed ID: 9788572
[TBL] [Abstract][Full Text] [Related]
34. HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts.
Hartwich J; Orr WS; Ng CY; Spence Y; Morton C; Davidoff AM
J Pediatr Surg; 2013 Jan; 48(1):39-46. PubMed ID: 23331791
[TBL] [Abstract][Full Text] [Related]
35. Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use.
Chen KTJ; Anantha M; Leung AWY; Kulkarni JA; Militao GGC; Wehbe M; Sutherland B; Cullis PR; Bally MB
Drug Deliv Transl Res; 2020 Feb; 10(1):202-215. PubMed ID: 31482519
[TBL] [Abstract][Full Text] [Related]
36. Improved Therapeutic Efficacy of Topotecan Against A549 Lung Cancer Cells with Folate-targeted Topotecan Liposomes.
Zhang J; Shi W; Xue G; Ma Q; Cui H; Zhang L
Curr Drug Metab; 2020; 21(11):902-909. PubMed ID: 32851958
[TBL] [Abstract][Full Text] [Related]
37. Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy.
Thomas AM; Kapanen AI; Hare JI; Ramsay E; Edwards K; Karlsson G; Bally MB
J Control Release; 2011 Mar; 150(2):212-9. PubMed ID: 21094191
[TBL] [Abstract][Full Text] [Related]
38. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity.
Semple SC; Leone R; Wang J; Leng EC; Klimuk SK; Eisenhardt ML; Yuan ZN; Edwards K; Maurer N; Hope MJ; Cullis PR; Ahkong QF
J Pharm Sci; 2005 May; 94(5):1024-38. PubMed ID: 15793796
[TBL] [Abstract][Full Text] [Related]
39. Image-guided thermosensitive liposomes for focused ultrasound drug delivery: Using NIRF-labelled lipids and topotecan to visualise the effects of hyperthermia in tumours.
Centelles MN; Wright M; So PW; Amrahli M; Xu XY; Stebbing J; Miller AD; Gedroyc W; Thanou M
J Control Release; 2018 Jun; 280():87-98. PubMed ID: 29723616
[TBL] [Abstract][Full Text] [Related]
40. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.
Gholizadeh S; Dolman EM; Wieriks R; Sparidans RW; Hennink WE; Kok RJ
Pharm Res; 2018 Mar; 35(4):85. PubMed ID: 29516187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
